SAN DIEGO, Jan 05, 2010 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) announced today that the company will webcast its presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, on January 12, 2010. The live webcast is scheduled to begin at 2:30p.m. ET and will feature an overview of the company by Jay Flatley, president and chief executive officer, followed by a question and answer session.
The company will also webcast the 2010 Illumina R&D Day from its Hayward, CA, facility on January 14, 2010. This event is scheduled to begin at 5:00p.m. ET.
The session will include presentations by Mr. Flatley and other members of Illumina's senior management team. The meeting will provide a comprehensive review of the company's product portfolio and market opportunities.
Both live webcasts can be accessed under the "Company/Investors" tab of Illumina's web site at www.illumina.com.
About Illumina
Illumina (www.illumina.com) is the leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any obligation to and do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
+858-882-6822
wgrabill@illumina.com
